Navigation Links
Silence Therapeutics Announces Board Changes
Date:7/1/2008

interfering RNA ('siRNA') molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including increased stability against nuclease degradation. In addition, the Company has developed a proprietary systemic delivery system, AtuPLEX. This system enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake.

Silence's lead internal product, Atu027, is a proprietary AtuRNAi molecule in preclinical development for systemic cancer indications. Atu027 has successfully completed single and repeat dose toxicology and geno-toxicology studies, as well as a 28-day toxicology study using multiple dosing regimens. Silence plans a regulatory filing in 2008 to commence clinical trials for Atu027.

In March 2008, Silence Therapeutics announced a collaboration with AstraZeneca (LSE: AZN) focused on the development of a range of novel delivery approaches for siRNA molecules. Under the terms of the agreement both Silence Therapeutics and AstraZeneca will be allowed to commercialize the truly novel delivery systems that the two partners develop together.

In July 2007, Silence Therapeutics formed its first research and development collaboration with AstraZeneca to develop novel AtuRNAi therapeutics against five specific targets, including those in respiratory indications. This collaboration was the first industry validation of the potential application of Silence Therapeutics' proprietary AtuRNAi molecules and solidified the Company's leadership position in field of RNAi therapeutics.

The Company's AtuRNAi technology also has been sublicensed to Pfizer via Quark's license to them of the compound RTP-801i-14 for the treatment of age-related macular degeneration (AMD) and a number of other indications. This compound entered the clinic in early 2007. Silence Therapeutics also has licensed to Quark rights to the AtuRNAi structure for Quark
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
2. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
3. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
10. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 2Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 3Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 4Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 5Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 6Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 7Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 8Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 9Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 2Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 3Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 4Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 6Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 7Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 2Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 3Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 4Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 5Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 6Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 7Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 8Diplomat Specialty Pharmacy Honored By Inc Magazine As One Of The Nations Fastest Growing Companies 54351 1Diplomat Specialty Pharmacy Honored By Inc Magazine As One Of The Nations Fastest Growing Companies 54351 2New Contract Awards May Shift Thousands of Medicaid Enrollees in Michigan 54347 1New Contract Awards May Shift Thousands of Medicaid Enrollees in Michigan 54347 2New Antibiotics May Target Cancer Causing Proteins 54343 1